尿激酶

CT导向置管加尿激酶灌注引流治疗脑内血肿108例

CT-guided catherization plus urokinase perfusion and drainage for intracerebral hematoma

测定尿激酶含量夹心法ELISA的建立

Establishment of a sandwich ELISA for measuring urokinase ( UK ) antigen

CT定位钻孔血肿抽吸尿激酶溶解治疗高血压脑出血

The treatment of hypertensive intracerebral hemorrhage by CT guided

结果表明，豆豉提取物的溶栓活性为0.326-161.972尿激酶单位／mL。

The fibrinolysis activities were from 0.326 to 161.972 UK / mL.

RT-PCR检测胃癌组织中尿激酶型纤溶酶原激活剂mRNA水平表达

Expression of Urokinase-type Plasminogen Activator mRNA in Gastric Cancer Tissues

尿激酶原cDNA在中国仓鼠卵巢细胞中的高效表达（Ⅰ）

High-level expression of pro-urokinase cDNA in Chinese hamster ovary cell line (ⅰ)

尿激酶受体反义RNA抑制人乳腺癌细胞的侵袭作用

Inhibition of Invasiveness of Human Breast Cancer Cells by Antisense RNA for Urokinase Receptor

尿激酶受体基因反义RNA转移体系的建立及其在白血病研究中的应用

Establishment of Urokinase Receptor Gene Antisense RNA Transfer System and Its Application in Leukemia Research

人尿激酶受体cDNA的克隆及序列测定

CDNA Cloning and Sequencing of Human Urokinase Receptor

国产重组人尿激酶原治疗ST段抬高性急性心肌梗死41例

Recombinant human prourokinase for 41 cases of acute myocardial infarction with elevated ST - segment

尿激酶联合氯吡格雷阿司匹林治疗急性ST段抬高型心肌梗塞疗效

Efficiency of urokinase combined clopidogrel and aspirin in the patients with ST-segment elevation myocardial infarction

A组溶栓治疗组19例，B溶栓治疗组17例，A组与B组的尿激酶用量及再通率分别是100万Iu、200万Iu和63.1%、82.3%（P>0.05）。

A and B groups with thrombolytic therapy are 19 and 17 cases respectively .

CT导向血肿穿刺吸除加尿激酶冲洗治疗高血压脑出血

The CT lead toes the hematoma to drill to drainage by to add the urokinase to flush to cure the hypertensive intracerebral hemorrhage

关节盘前移位对关节滑膜尿激酶型纤溶酶原激活剂及其1型抑制剂mRNA表达的影响

Effect of Disc Displacement on mRNA Expression of Urokinase Plasminogen Activator and Its Inhibitor - 1 in Synovial Tissues

尿激酶组与去纤酶组比较：血管再通率分别为58.1%对40.6%（P＜0.001）；

The reopening rate of infarct-related artery within two hours was 58.1 % in the urokinase group and 40.6 % in the defibrase group ( P0.001 ) .

300万U尿激酶溶栓治疗急性心肌梗塞231例的临床初步总结

The report on thrombolytic therapy using 300 million U urokinase in 231 cases with acute myocardial infarction

方法：采用自制简易定位装置，借助CT扫描定向穿刺血肿，进行抽吸、尿激酶灌洗治疗。

Methods : Using simple equipment which was made by ourselves , hypertensive intracerebral hematomas was removed by CT-guided aspiration and infusion of urokinase .

尿激酶联合雷公藤多甙片治疗IgA肾病的临床观察

Clinical Observation on Urokinase Combined with Tripterygium Wilfordii Polyglycoside For IgA Nephropathy

术后立即复查CT确定残留血肿量，决定是否进行进一步的血肿腔尿激酶（UK）溶解治疗。

After the operation , CT was used immediately to determine left hematoma to decide if further of dissolving UK treatment was necessary .

方法：在小剂量尿激酶治疗的前中后分3次观察TCD前后对照。

Method : Observe the change before and after the treatment .

急性心肌梗塞尿激酶溶栓治疗早期ST段变化对预后的评价

Evaluation of Prognosis by Early ST segment Analysis in Patients with Acute Myocardial Infarction Through Venous Urokinase Therapy

人尿激酶原cDNA序列缺失突变体的构建及表达

The Construction and Expression of Human Pro urokinase cDNA Coding Deleted Mutant at 150 ~ 156 Amino Acids

含尿激酶mRNA的人胚肾培养细胞的poly（A）+RNA的提取及鉴定

Extraction and identification of poly ( a ) ~ + RNA containing urokinase mRNA from primary fetal kidney cell cultures

方法：运用下腔静脉结扎法制造大鼠血栓形成模型，研究PLC对实验性血栓形成的影响并与尿激酶（UK）比较；

Methods : The effect of PLC on experimental thrombosis was studied by inferior caval vein ligature thrombosis model and was compared with UK .

尿激酶联合血管紧张素转换酶抑制剂治疗IgA肾病的随访观察

Follow-up of the Effect on the Urokinase Combined with Angiotensin Converting Enzyme Inhibitor on IgA Nephropathy

小剂量尿激酶联合激素和福辛普利治疗中重型IgA肾病的临床研究

Effect of A Low Dosed Urokinase plus Prednisone and Fosinopril on Moderate and Severe IgA Nephropathy

可溶性尿激酶型纤溶酶原激活物受体在RA患者血浆和滑液的水平及其临床意义

Detection and significance of soluble urokinase-type plasminogen activator receptor in plasma and synovial fluid of patients with rheumatoid arthritis

尿激酶和前列腺素E1联合溶解深静脉血栓的临床研究

Clinical Study on Thrombolysis of Deep Venous Thrombosis Using Urokinase Plus Prostaglandin E 1

目的：评价动脉内灌注尿激酶（UK）治疗急性缺血性脑卒中的安全性和疗效。

Objective : To evaluate the therapeutic effect and safety of intraarterial infusion of Urokinase ( UK ) for the treatment of acute ischemic cerebral apoplexy .

目的：探讨AMI患者尿激酶治疗后相关细胞因子水平的变化及检测价值。

Objective To explore the changes of the serum levels of related cytokines after urokinase therapy in patients with AMI .